The MAP Group, a pan-European specialist pharmaceutical and biotechnology strategic consultancy focused on driving therapies through the complex medical, regulatory and market access landscape to ...

There are challenges to be overcome and risks to be had, but the value strategic partnerships bring to companies should not ...

Global investment giant TPG Group is set to expand its footprint in India’s pharmaceutical packaging industry with its ... marking a strategic entry of TPG into the growing pharmaceutical ...

Pharma and medtech companies are invited to join a project on PFAS exposure, emissions and end-of-life management in the ...

According to the survey’s 600 patient group respondents, the overall reputation of the industry had declined ... suggest three important strategic pointers for pharma: Companies need to avoid ...

The examples of strategic decisions taken by pharma companies in the Oliver Wyman report represent several initiatives of a wider effort in the industry ... state off the map,or turns an entire ...

Operator Hello, and welcome to the fourth quarter and full year 2024 Teva Pharmaceutical Industries earnings conference call.

Later during the conference, Takeda CEO Christophe Weber laid out the company's top pipeline prospects, a group of 6 drugs ... T-cell engager As the biopharma industry gains more interest in ...

The Property & Liability Resource Bureau (PLRB) is proud to announce its partnership with the Spencer Educational Foundation, a leader in fostering the development of future insurance and risk ...

Envisioning future outcomes can deliver insights on how to tackle antibiotic resistance and other major global problems ...

The global Oligonucleotide CDMO Market, valued at US$2.33 billion in 2023, is forecasted to grow at a robust CAGR of 21.8%, reaching US$2.51 billion in 2024 and an impressive US$6.73 billion by 2029.